Background
• Breast cancer(BC) is the leading cause of death worldwide and is the most common type of cancer in women. As breast screening rates have increased, more cases have been found at earlier stages.
• Identifying a biomarker to detect BC at an early stage will improve clinical outcomes.
•After treatment with curative surgery, Identification of patients with residual disease who are at high risk of relapse may be used to stratify patients to adjuvant therapy.
DEL-1
: Developmental endothelial locus-1 protein
• Also known as Epidermal growth factor-like repeats and discoidin I-like domains 3 (EDIL3)
• First identified as an extracellular matrix protein expressed by endothelial cells during embryonic vascular development
• Also shown to promote adhesion of endothelial cells through its interaction with integrin receptors. Method (1) • Sample Collection for the optimal time of blood draw -To identify the optimal time of sampling after surgery, blood samples were serially collected at post-operative day (POD) 1, 3, 5, and 7 (N=22) 
Del-1
Characteristics N % Del-1 at diagnosis, mean ± SD 1.23 ± 0.46 • Lower del-1 level in plasma after surgery was associated with a better survival.
• More significant differences with cut of value 0.4.
• Postop del-1 in plasma may reflect residual tumor burden. Hormone-responsive HER2-overexpressing Triple negative
Conclusion
•As the current prospective cohort study demonstrated a normalization of exosomal Del-1 after curative surgery, exosomal Del-1 can be confirmed as a potent diagnostic biomarker for breast cancer.
•High Del-1 level after surgery seems related with early relapse suggesting a potential prognostic marker by identifying the existence of residual tumor.
•The minimally invasive method with high sensitivity and specificity based on the molecular biomarker, Del-1-positive circulating exosomes, is promising for the early diagnosis of breast cancer using only one drop of blood.
